Home › Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
 

Keywords :   


Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

2016-10-19 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: met study primary medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04Topigs Norsvin USA appoints Pinilla as director of technical services
29.04Essity Upgrades Paper Mill in U.K.
29.04Konica Minolta receives EcoVadis Gold Medal sustainability rating
29.04Registration opens for Labelexpo Americas 2024
29.04Nippon Paint Marine Joins Global Industry Alliance for Marine Biosafety
29.04Sappi Europe announces milestone in Austria
29.04Snie¿ka Among Best Polish Employers According to Wprost Ranking
29.04Dantex announces new distributor agreement in France
More »